SIGHT Intrinsic Valuation and Fundamental Analysis - Gensight Biologics SA - Alpha Spread

Gensight Biologics SA
PAR:SIGHT

Watchlist Manager
Gensight Biologics SA Logo
Gensight Biologics SA
PAR:SIGHT
Watchlist
Price: 0.395 EUR 5.05% Market Closed
Market Cap: 40.9m EUR
Have any thoughts about
Gensight Biologics SA?
Write Note

Intrinsic Value

SIGHT's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

The intrinsic value of one SIGHT stock under the Base Case scenario is 0.431 EUR. Compared to the current market price of 0.395 EUR, Gensight Biologics SA is Undervalued by 8%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

SIGHT Intrinsic Value
0.431 EUR
Undervaluation 8%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Gensight Biologics SA

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling SIGHT based on its intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?
How do you feel about SIGHT?
Bearish
Neutral
Bullish

Fundamental Analysis

Summary

 

 

 

 

View All Risks & Rewards
Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Wall St Estimates
Price Target
Loading
Revenue Forecast
Operating Income Forecast
Earnings Forecast
No Indicators Selected
Select Indicators
Investor Returns
Shareholder Yield
Dividend Safety
Dividend Yield
Dividend Payout Ratio
Buyback Yield
Debt Paydown Yield
No Indicators Selected
Select Indicators
Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

AI Assistant
AI Assistant
Ask me anything about Gensight Biologics SA

Provide an overview of the primary business activities
of Gensight Biologics SA.

What unique competitive advantages
does Gensight Biologics SA hold over its rivals?

What risks and challenges
does Gensight Biologics SA face in the near future?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Gensight Biologics SA.

Provide P/S
for Gensight Biologics SA.

Provide P/E
for Gensight Biologics SA.

Provide P/OCF
for Gensight Biologics SA.

Provide P/FCFE
for Gensight Biologics SA.

Provide P/B
for Gensight Biologics SA.

Provide EV/S
for Gensight Biologics SA.

Provide EV/GP
for Gensight Biologics SA.

Provide EV/EBITDA
for Gensight Biologics SA.

Provide EV/EBIT
for Gensight Biologics SA.

Provide EV/OCF
for Gensight Biologics SA.

Provide EV/FCFF
for Gensight Biologics SA.

Provide EV/IC
for Gensight Biologics SA.

Show me price targets
for Gensight Biologics SA made by professional analysts.

What are the Revenue projections
for Gensight Biologics SA?

How accurate were the past Revenue estimates
for Gensight Biologics SA?

What are the Net Income projections
for Gensight Biologics SA?

How accurate were the past Net Income estimates
for Gensight Biologics SA?

What are the EPS projections
for Gensight Biologics SA?

How accurate were the past EPS estimates
for Gensight Biologics SA?

What are the EBIT projections
for Gensight Biologics SA?

How accurate were the past EBIT estimates
for Gensight Biologics SA?

Compare the revenue forecasts
for Gensight Biologics SA with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Gensight Biologics SA and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Gensight Biologics SA against its competitors.

Analyze the profit margins
(gross, operating, and net) of Gensight Biologics SA compared to its peers.

Compare the P/E ratios
of Gensight Biologics SA against its peers.

Discuss the investment returns and shareholder value creation
comparing Gensight Biologics SA with its peers.

Analyze the financial leverage
of Gensight Biologics SA compared to its main competitors.

Show all profitability ratios
for Gensight Biologics SA.

Provide ROE
for Gensight Biologics SA.

Provide ROA
for Gensight Biologics SA.

Provide ROIC
for Gensight Biologics SA.

Provide ROCE
for Gensight Biologics SA.

Provide Gross Margin
for Gensight Biologics SA.

Provide Operating Margin
for Gensight Biologics SA.

Provide Net Margin
for Gensight Biologics SA.

Provide FCF Margin
for Gensight Biologics SA.

Show all solvency ratios
for Gensight Biologics SA.

Provide D/E Ratio
for Gensight Biologics SA.

Provide D/A Ratio
for Gensight Biologics SA.

Provide Interest Coverage Ratio
for Gensight Biologics SA.

Provide Altman Z-Score Ratio
for Gensight Biologics SA.

Provide Quick Ratio
for Gensight Biologics SA.

Provide Current Ratio
for Gensight Biologics SA.

Provide Cash Ratio
for Gensight Biologics SA.

What is the historical Revenue growth
over the last 5 years for Gensight Biologics SA?

What is the historical Net Income growth
over the last 5 years for Gensight Biologics SA?

What is the current Free Cash Flow
of Gensight Biologics SA?

Discuss the annual earnings per share (EPS)
trend over the past five years for Gensight Biologics SA.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Gensight Biologics SA

Current Assets 6.5m
Cash & Short-Term Investments 2.1m
Receivables 2.4m
Other Current Assets 2m
Non-Current Assets 2.6m
Long-Term Investments 502k
PP&E 2m
Intangibles 75k
Other Non-Current Assets 1k
Current Liabilities 25.3m
Accounts Payable 5.6m
Accrued Liabilities 1.8m
Other Current Liabilities 17.8m
Non-Current Liabilities 14.5m
Long-Term Debt 6.2m
Other Non-Current Liabilities 8.4m
Efficiency

Earnings Waterfall
Gensight Biologics SA

Revenue
1.3m EUR
Operating Expenses
-31m EUR
Operating Income
-29.7m EUR
Other Expenses
3.5m EUR
Net Income
-26.2m EUR

Free Cash Flow Analysis
Gensight Biologics SA

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

SIGHT Profitability Score
Profitability Due Diligence

Gensight Biologics SA's profitability score is 22/100. The higher the profitability score, the more profitable the company is.

Exceptional Revenue Growth Forecast
Exceptional ROE
ROE is Increasing
Negative 1-Year Revenue Growth
22/100
Profitability
Score

Gensight Biologics SA's profitability score is 22/100. The higher the profitability score, the more profitable the company is.

SIGHT Solvency Score
Solvency Due Diligence

Gensight Biologics SA's solvency score is 22/100. The higher the solvency score, the more solvent the company is.

Low D/E
Positive Net Debt
Short-Term Solvency
Long-Term Solvency
22/100
Solvency
Score

Gensight Biologics SA's solvency score is 22/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

SIGHT Price Targets Summary
Gensight Biologics SA

Wall Street analysts forecast SIGHT stock price to drop over the next 12 months.

According to Wall Street analysts, the average 1-year price target for SIGHT is 0.388 EUR with a low forecast of 0.364 EUR and a high forecast of 0.42 EUR.

Lowest
Price Target
0.364 EUR
8% Downside
Average
Price Target
0.388 EUR
2% Downside
Highest
Price Target
0.42 EUR
6% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for SIGHT?

Click here to dive deeper.

Shareholder Yield

Current shareholder yield for SIGHT is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Want to learn more about SIGHT dividends, buybacks, and debt paydown yield?

Click here to dive deeper.

SIGHT Price
Gensight Biologics SA

1M 1M
+7%
6M 6M
-13%
1Y 1Y
-34%
3Y 3Y
-95%
5Y 5Y
-64%
10Y 10Y
-95%
Annual Price Range
0.395
52w Low
0.29
52w High
0.704
Price Metrics
Average Annual Return 61.82%
Standard Deviation of Annual Returns 106.02%
Max Drawdown -97%
Shares Statistics
Market Capitalization 40.9m EUR
Shares Outstanding 103 457 652
Percentage of Shares Shorted
N/A

Competitive Landscape

Profile

Gensight Biologics SA Logo
Gensight Biologics SA

Country

France

Industry

Biotechnology

Market Cap

40.9m EUR

Dividend Yield

0%

Description

GenSight Biologics SA is a clinical-stage gene therapy company. The company is headquartered in Paris, Ile-De-France. The company went IPO on 2016-07-13. The firm develops and commercializes gene therapy-based treatments of retinal degenerative diseases. The company develops approaches to prevent retinal degeneration in selected pathological conditions and to restore vision in patients suffering from low vision or blindness. The firm intends notably to develop a gene replacement therapy for Leber's hereditary optic neuropathy (LHON) and an optogenetic therapy for retinitis pigmentosa (RP).

Contact

ILE-DE-FRANCE
Paris
74 Rue du Faubourg Saint-Antoine
+33176217220.0
www.gensight-biologics.com

IPO

2016-07-13

Employees

33

Officers

See Also

Discover More
What is the Intrinsic Value of one SIGHT stock?

The intrinsic value of one SIGHT stock under the Base Case scenario is 0.431 EUR.

Is SIGHT stock undervalued or overvalued?

Compared to the current market price of 0.395 EUR, Gensight Biologics SA is Undervalued by 8%.

Back to Top